The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

With a market cap of $62.4 billion, Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Regeneron's oncology platform is poised to be a significant growth driver in the next decade. Read why REGN stock remains a ...

Of those 49 drugs, 39 were classified as having high added therapeutic benefit, and accounted for estimated post-rebate Medicare spending totaling $26 billion. But "cancer drugs o ...

Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that the completion ...

In PD-(L)1 resistant hot tumors, solnerstotug+cemiplimab showed 14% ORR, nearly 3x higher than historical PD-(L)1 rechallenge response rates Solnerstotug remains well tolerated, with no dose ...

and efficacy of solnerstotug as both a monotherapy and in combination with Regeneron’s PD-1 inhibitor Libtayo ® (cemiplimab) in patients with advanced solid tumors. Recent updates include ...

Detailed price information for Sensei Biotherapeutics Inc (SNSE-Q) from The Globe and Mail including charting and trades.

Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara, and others. On March 14, Evan Seigerman, an analyst from BMO Capital, maintained a Buy rating on the stock with a price target of $903.

Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara, and others. On March 14, Evan Seigerman, an analyst from BMO Capital, maintained a Buy rating on the stock with a price target of $903.